<DOC>
	<DOCNO>NCT02895958</DOCNO>
	<brief_summary>Evaluation Zepatier community-based setting among cirrhotic non-cirrhotic patient stable opiate substitution therapy .</brief_summary>
	<brief_title>The Dublin Zepatier Fibrovan Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>1 . Subject ≥18 year age . 2 . Subject must HCV treatment naive . Subject willing able understand provide write informed consent prior participation study . 3 . Documented HCV infection ( PCR positive ) , HCV RNA level &gt; 10x4 IU/ml . 4 . Documented HCV genotype 1 4 . 5 . Documented HIV HBV negative 6 . A female eligible enter participate study : nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ) ; , 7 . Childbearing potential , negative pregnancy test ( serum βHCG ) screen agree acceptable barrier and/or hormonal method contraception ( contraception method must use consistently correctly , i.e. , accordance approve product label instruction physician ) : Sterilization ( female subject male partner female subject ) . Male female subject must agree 7 month posttreatment contraception take ribavirin . 8 . Stable attender site enrolment . ( receive OAT least 3 month enrolment least 80 % adherent OAT appointment ) 9 . Venous access available blood monitoring . 10 . Fibroscan indicate disease activity per HSE Hepatitis C Advisory Group guideline . 11 . Safety blood do prior study include HGB &gt; 9.5g/dL , platelet &gt; 75,000 , AST &lt; 10x ULN , albumin level &gt; 30g/L . 1 . Child Pugh B 2 . HCV nonG1/G4 3 . History decompensated liver disease 4 . Laboratory exclusion include platelet count &lt; 75,000 , albumin &lt; 30gm/L , Alanine aminotransferase ( ALT ) &gt; 10 time upper limit normal ( ULN ) . 5 . Subject enrol one investigational drug protocol , may impact assessment HCV treatment Zepatier ( +/_ ribavirin ) . 6 . Subject , opinion investigator , unable complete study dose period protocol evaluation assessment . 7 . Patients alcohol drug use problem view investigator compromise adherence compliance study exclude . 8 . Subject either pregnant breastfeeding . 9 . Subject suffers serious medical condition ( pancreatitis , diabetes , congestive heart failure , cardiomyopathy cardiac dysfunction ) , opinion Investigator , would compromise safety subject . 10 . Subject preexist mental , physical , substance abuse disorder , opinion Investigator , may interfere subject 's ability comply dose schedule protocol evaluation assessment . 11 . Subject history inflammatory bowel disease intestinal malignancy , intestinal ischemia , malabsorption , gastrointestinal dysfunction , , opinion Investigator , may interfere drug absorption render subject unable take oral medication . 12 . Subject acute laboratory abnormality screening , , opinion Investigator , would preclude subject 's participation study investigational compound . If subject find acute Grade 4 laboratory abnormality screening , test may repeat within 45day screen window . Any verified Grade 4 laboratory abnormality would exclude subject study participation . 13 . Subject receive treatment radiation therapy cytotoxic chemotherapeutic agent within 28 day prior Screening , anticipate need agent within study period . 14 . Subjects require treatment contraindicate medication ( outline SPC ) within 14 day commencement investigational product , anticipate need study . 15 . Subject history allergy treatment product excipients therein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>